Viscoelastic testing in COVID-19: a possible screening tool for severe disease

Authors

Jay S. Raval, Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA
Allison E. Burnett, Department of Pharmacy, University of New Mexico, Albuquerque, New Mexico, USA
Marian A. Rollins-Raval, Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA
Joseph R. Griggs, Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA
Lizabeth Rosenbaum, Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA, Vitalant, Albuquerque, New Mexico, USA
Nathan D. Nielsen, Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA
Michelle S. Harkins, Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA

Document Type

Article

Publication Date

6-1-2020

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) that manifests with variable severity. 1 A subset of symptomatic individuals develop proinflammatory or prothrombotic profiles requiring additional testing and interventions. 2-5 It is unclear which COVID-19 patients will ultimately develop severe disease that would have benefitted from early and aggressive interventions.

Recommended Citation

Raval JS, Burnett AE, Rollins-Raval MA, Griggs JR, Rosenbaum L, Nielsen ND, Harkins MS. Viscoelastic testing in COVID-19: a possible screening tool for severe disease? Transfusion. 2020 Jun;60(6):1131-1132. doi: 10.1111/trf.15847. Epub 2020 May 22. PMID: 32374920; PMCID: PMC7267656.``````````````````````````````